Hydrotherapy in mucopolysaccharidosis II

Not Applicable

• Conditions: Mucopolysaccharidosis type II; Nutritional, Metabolic, Endocrine; Mucopolysaccharidosis, type II

• Registration Number: ISRCTN16919215
• Lead Sponsor: Salford Royal Organisation, Northern Care Alliance NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-10-25
• Last Update Posted: 13 November 2023
• Study Completion: 2024-10-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: Male
• Target Recruitment: 5

Inclusion Criteria

1. Adult MPS II patients (Hunter syndrome; all males aged 18-58 years), who suffer from joint pain and stiffness and/or post-surgical musculoskeletal pain, not responding to analgesic agents
2. Patients with reduced mobility and wheelchair reliance
3. Patients are able to give consent and feedback. In patients with limited capacity, their carers/parents may be asked to help complete the questionnaires.
4. Participants who pass the Trust hydrotherapy risk assessment at baseline

Exclusion Criteria

1. Contraindications to standard hydrotherapy: acute diarrhoea or vomiting, recent acute cerebral vascular accident (CVA)/deep venous thrombosis (DVT)/pulmonary embolism (PE), resting angina, resting shortness of breath, uncontrolled cardiac failure, weight in excess of evacuation equipment, proven chlorine allergy.
2. More severely incapacitated (severe learning needs) and/or immobile patients.
3. The objective Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score will be used to identify and exclude patients who suffer from predominantly neuropathic pain (rather than musculoskeletal nociceptive-driven pain). This assessment will be performed by a pain specialist.

Study & Design

• Study Type: Interventional
• Study Design: Not specified